Xeris Biopharma Holdings Inc
NASDAQ:XERS 2:44:33 PM EDT
Products
Xeris Biopharma Says FDA Grants Orphan-Drug Exclusivity For Recorlev
Published: 01/30/2023 12:48 GMT
Xeris Biopharma Holdings Inc (XERS) - Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®.
Xeris Biopharma Holdings Inc - Xeris is Entitled to Seven Years of Orphan-drug Market Exclusivity From Its FDA Approval Date of December 30, 2021.
Xeris Biopharma-regulatory Exclusivity in Addition to Patent Exclusivity Under U.S. Patents Covering Recorlev'stherapeutic Use,extending to March 2040.
Xeris Biopharma Holdings Inc - Xeris is Entitled to Seven Years of Orphan-drug Market Exclusivity From Its FDA Approval Date of December 30, 2021.
Xeris Biopharma-regulatory Exclusivity in Addition to Patent Exclusivity Under U.S. Patents Covering Recorlev'stherapeutic Use,extending to March 2040.